Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience
Open Access
- 1 September 2018
- journal article
- research article
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 10, 371-378
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute
- National Heart, Lung, and Blood Institute (P40HL116242)
- Celgene
- St. Baldrick's Foundation (PO1 CA008748)
- National Institutes of Health (P30 CA008748, P50-CA190991, R01CA114218, R01-CA177476)
This publication has 29 references indexed in Scilit:
- Biosafety Features of Lentiviral VectorsHuman Gene Therapy, 2013
- Replication-Competent Retroviruses in Gene-Modified T Cells Used in Clinical Trials: Is It Time to Revise the Testing Requirements?Molecular Therapy, 2012
- Stem-Cell Gene Therapy for the Wiskott–Aldrich SyndromeNew England Journal of Medicine, 2010
- LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1Science, 2003
- A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2003
- Supplemental Guidance on Testing for Replication-Competent Retrovirus in Retroviral Vector-Based Gene Therapy Products and During Follow-up of Patients in Clinical Trials Using Retroviral VectorsHuman Gene Therapy, 2001
- Safety Testing for Replication-Competent Retrovirus Associated with Gibbon Ape Leukemia Virus-Pseudotyped Retroviral VectorsHuman Gene Therapy, 2001
- Characterization of a Replication-Competent Retrovirus Resulting from Recombination of Packaging and Vector SequencesHuman Gene Therapy, 1994
- Infection of Human Cells with Murine Amphotropic Replication-Competent RetrovirusesHuman Gene Therapy, 1993
- Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer.Journal of Experimental Medicine, 1992